[{"id":"e9547fb4-4cd2-4f5f-b4e3-ae7528896751","acronym":"FIRST-308","url":"https://clinicaltrials.gov/study/NCT05948475","created_at":"2023-07-17T14:08:53.898Z","updated_at":"2024-07-02T16:34:27.046Z","phase":"Phase 3","brief_title":"Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma","source_id_and_acronym":"NCT05948475 - FIRST-308","lead_sponsor":"TransThera Sciences (Nanjing), Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • irinotecan • tinengotinib (TT-00420)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 12/20/2023","start_date":" 12/20/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-06-12"},{"id":"1724693c-3f92-4147-a8fc-47d82f80159d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04742959","created_at":"2023-12-01T18:15:51.667Z","updated_at":"2024-07-02T16:35:07.274Z","phase":"Phase 1/2","brief_title":"Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04742959","lead_sponsor":"TransThera Sciences (Nanjing), Inc.","biomarkers":" FGFR","pipe":"","alterations":" ","tags":["FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • tinengotinib (TT-00420)"],"overall_status":"Completed","enrollment":" Enrollment 203","initiation":"Initiation: 03/14/2021","start_date":" 03/14/2021","primary_txt":" Primary completion: 02/20/2024","primary_completion_date":" 02/20/2024","study_txt":" Completion: 02/20/2024","study_completion_date":" 02/20/2024","last_update_posted":"2024-04-26"},{"id":"e391f2a5-896d-4821-b066-fdd97cba862d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04919642","created_at":"2021-06-10T01:52:34.634Z","updated_at":"2024-07-02T16:35:07.347Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma","source_id_and_acronym":"NCT04919642","lead_sponsor":"TransThera Sciences (Nanjing), Inc.","biomarkers":" FGFR2 • FGFR","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR1 mutation • FGFR1 fusion • FGFR wild-type","tags":["FGFR2 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR mutation • FGFR1 mutation • FGFR1 fusion • FGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tinengotinib (TT-00420)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 12/07/2021","start_date":" 12/07/2021","primary_txt":" Primary completion: 02/28/2024","primary_completion_date":" 02/28/2024","study_txt":" Completion: 02/28/2024","study_completion_date":" 02/28/2024","last_update_posted":"2024-04-26"},{"id":"0873a687-5c25-4715-8acf-d74951c994f9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03654547","created_at":"2023-11-24T18:58:25.547Z","updated_at":"2024-07-02T16:35:24.753Z","phase":"Phase 1","brief_title":"Safety of TT-00420 (Tinengotinib) Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer","source_id_and_acronym":"NCT03654547","lead_sponsor":"TransThera Sciences (Nanjing), Inc.","biomarkers":" STAT3","pipe":"","alterations":" ","tags":["STAT3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tinengotinib (TT-00420)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 02/28/2024","study_completion_date":" 02/28/2024","last_update_posted":"2024-01-03"},{"id":"e671e677-64c8-4b01-a7f3-faf12dd72e4c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05253053","created_at":"2022-02-23T19:55:13.549Z","updated_at":"2024-07-02T16:35:24.710Z","phase":"Phase 1/2","brief_title":"To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05253053","lead_sponsor":"TransThera Sciences (Nanjing), Inc.","biomarkers":" HER-2 • FGFR2","pipe":" | ","alterations":" PD-L1 expression • HER-2 negative","tags":["HER-2 • FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • albumin-bound paclitaxel • tinengotinib (TT-00420)"],"overall_status":"Recruiting","enrollment":" Enrollment 114","initiation":"Initiation: 04/13/2022","start_date":" 04/13/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-03"},{"id":"494b4eb7-0657-41d7-a7f8-9fbcecaea223","acronym":"","url":"https://clinicaltrials.gov/study/NCT06057571","created_at":"2023-09-28T15:10:53.562Z","updated_at":"2024-07-02T16:35:24.847Z","phase":"Phase 2","brief_title":"Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor","source_id_and_acronym":"NCT06057571","lead_sponsor":"TransThera Sciences (Nanjing), Inc.","biomarkers":" FGFR2","pipe":"","alterations":" ","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tinengotinib (TT-00420)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 11/17/2023","start_date":" 11/17/2023","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2024-01-01"}]